All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Centhaquine
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Lyfaquin
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
Lyfaquin® increases blood pressure and cardiac output by augmenting venous blood return to the heart and enhancing tissue blood perfusion by arterial dilatation (sympatholytic function due to central alpha-2A adrenergic stimulation).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Centhaquine
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Centhaquine's pivotal phase III study in India in hypovolemic shock demonstrated a transformational improvement over standard of care in increasing blood pressure and reducing blood lactate levels.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexamethasone
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Guggenheim Securities
Deal Size: $21.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 20, 2020
Details:
EyePoint intends to use the net proceeds of the offering to continue to fund the commercialization and expand the access of DEXYCU® and YUTIQ® and for general corporate purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexamethasone
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Vision Center Network of America
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 18, 2020
Details:
The agreement will enable VCNA physicians to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexamethasone
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Ocumension Therapeutics
Deal Size: $14.0 million Upfront Cash: $2.0 million
Deal Type: Licensing Agreement February 03, 2020
Details:
Ocumension will receive exclusive rights to develop and commercialize the product in Mainland China, Hong Kong, Macau and Taiwan.